The Friedewald Equation
The Friedewald formula estimates the low-density lipoprotein cholesterol concentration from three measurable blood lipid values obtained during a standard lipid panel. This equation has remained the reference method in clinical practice since its publication by Friedewald, Levy, and Fredrickson.
LDL = TC − HDL − (0.2 × TG)
TC— Total cholesterol measured in mg/dLHDL— High-density lipoprotein (protective cholesterol) in mg/dLTG— Triglycerides in mg/dL
Understanding Your Results
LDL-C targets depend on your individual cardiovascular risk profile. The European Society of Cardiology recommends:
- Below 115 mg/dL for individuals with low coronary risk (SCORE <5%)
- Below 100 mg/dL for those with intermediate risk (SCORE 5–10%)
- Below 70 mg/dL for high-risk patients (SCORE >10%) or those with established cardiovascular disease
Oxidized LDL particles penetrate the arterial endothelium, triggering chronic inflammation and plaque formation. Even modest reductions in LDL-C yield measurable improvements in event rates, particularly in secondary prevention settings.
Rearranging the Formula
The Friedewald equation can be rearranged to solve for total cholesterol if you know LDL, HDL, and triglycerides:
TC = LDL + HDL + (0.2 × TG)
This transformation is useful when comparing results across different laboratory reports or cross-checking your lipid panel values. Ensure all measurements are in the same units (typically mg/dL) before performing the calculation.
When to Use and When Not to Use This Calculation
The Friedewald method is reliable under specific conditions; deviations reduce accuracy.
- Fasting requirement — Blood samples must be drawn after a 9–12 hour fast. Non-fasting triglyceride measurements can elevate values artificially, skewing the LDL calculation downward and potentially masking risk.
- Triglyceride boundaries — The formula assumes triglycerides between 100 and 400 mg/dL. Beyond these limits, the constant 0.2 coefficient becomes unreliable, and direct LDL measurement via ultracentrifugation or ion-mobility analysis is necessary.
- Genetic lipid disorders — Patients with Type I or III hyperlipoproteinemia exhibit abnormal lipoprotein distributions that violate the formula's assumptions. Direct LDL-C measurement is mandatory in these cases to avoid treatment errors.
- Very high triglycerides — Severe hypertriglyceridemia (>400 mg/dL) often reflects chylomicaemia or VLDL overproduction, conditions where the Friedewald estimate becomes unreliable and direct measurement is clinically essential.
Lowering Elevated LDL-C
Lifestyle modification forms the foundation of LDL management, but many patients require pharmacotherapy:
- Statins: First-line agents that inhibit cholesterol synthesis; moderate-to-high intensity regimens reduce LDL-C by 30–50%
- Ezetimibe: Blocks intestinal cholesterol absorption; typically lowers LDL by 15–20%
- PCSK9 inhibitors: Monoclonal antibodies that enhance LDL receptor clearance; achieve 40–60% reductions in non-responders
- Dietary fibre: Soluble fibre (oats, beans, legumes) binds cholesterol in the gut, promoting excretion
- Trans fat elimination: Remove processed foods and baked goods; each 2% caloric increase in trans fats raises LDL-C by ~1 mg/dL
- Regular aerobic exercise: 150 minutes weekly of moderate intensity raises HDL and modestly lowers triglycerides and LDL